RU2623062C2 - Новая терапия транстиретин-ассоциированного амилоидоза - Google Patents

Новая терапия транстиретин-ассоциированного амилоидоза Download PDF

Info

Publication number
RU2623062C2
RU2623062C2 RU2014114930A RU2014114930A RU2623062C2 RU 2623062 C2 RU2623062 C2 RU 2623062C2 RU 2014114930 A RU2014114930 A RU 2014114930A RU 2014114930 A RU2014114930 A RU 2014114930A RU 2623062 C2 RU2623062 C2 RU 2623062C2
Authority
RU
Russia
Prior art keywords
comt
inhibitor
ttr
transthyretin
group
Prior art date
Application number
RU2014114930A
Other languages
English (en)
Russian (ru)
Other versions
RU2014114930A (ru
Inventor
КАСАДО Марк СЕНТЕЯС
БОРОНАТ Рауль ИНСА
БОЛАНЬО Нурия РЕЙГ
БАТАЛЛА Нурия ГАВАЛЬДА
Original Assignee
Сом Инновэйшн Биотек, С.Л.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47076222&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=RU2623062(C2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Сом Инновэйшн Биотек, С.Л. filed Critical Сом Инновэйшн Биотек, С.Л.
Publication of RU2014114930A publication Critical patent/RU2014114930A/ru
Application granted granted Critical
Publication of RU2623062C2 publication Critical patent/RU2623062C2/ru

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/423—Oxazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/603—Salicylic acid; Derivatives thereof having further aromatic rings, e.g. diflunisal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
RU2014114930A 2011-10-24 2012-10-23 Новая терапия транстиретин-ассоциированного амилоидоза RU2623062C2 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP11382326.4 2011-10-24
EP11382326 2011-10-24
PCT/EP2012/070945 WO2013060668A1 (en) 2011-10-24 2012-10-23 New therapy for transthyretin-associated amyloidosis

Related Child Applications (1)

Application Number Title Priority Date Filing Date
RU2017119539A Division RU2747536C2 (ru) 2011-10-24 2012-10-23 Новая терапия транстиретин-ассоциированного амилоидоза

Publications (2)

Publication Number Publication Date
RU2014114930A RU2014114930A (ru) 2015-12-10
RU2623062C2 true RU2623062C2 (ru) 2017-06-21

Family

ID=47076222

Family Applications (2)

Application Number Title Priority Date Filing Date
RU2014114930A RU2623062C2 (ru) 2011-10-24 2012-10-23 Новая терапия транстиретин-ассоциированного амилоидоза
RU2017119539A RU2747536C2 (ru) 2011-10-24 2012-10-23 Новая терапия транстиретин-ассоциированного амилоидоза

Family Applications After (1)

Application Number Title Priority Date Filing Date
RU2017119539A RU2747536C2 (ru) 2011-10-24 2012-10-23 Новая терапия транстиретин-ассоциированного амилоидоза

Country Status (19)

Country Link
US (5) US9610270B2 (enExample)
EP (1) EP2770988B1 (enExample)
JP (1) JP6068484B2 (enExample)
KR (1) KR102017354B1 (enExample)
CN (1) CN103889407B (enExample)
AU (2) AU2012327275B2 (enExample)
BR (1) BR112014009322B1 (enExample)
CA (1) CA2852808C (enExample)
CL (1) CL2014000893A1 (enExample)
CY (1) CY1118151T1 (enExample)
ES (1) ES2593038T3 (enExample)
IL (1) IL231907B (enExample)
MX (2) MX347784B (enExample)
PL (1) PL2770988T3 (enExample)
PT (1) PT2770988T (enExample)
RU (2) RU2623062C2 (enExample)
SG (2) SG10201609933WA (enExample)
WO (1) WO2013060668A1 (enExample)
ZA (1) ZA201402546B (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2770988T (pt) * 2011-10-24 2016-09-05 Som Innovation Biotech S L Nova terapêutica para a amiloidose associada à transtirretina
EP3185957B1 (en) * 2014-08-29 2022-06-01 Alnylam Pharmaceuticals, Inc. Patisiran for use in treating transthyretin mediated amyloidosis
EP3275433A1 (en) * 2016-07-29 2018-01-31 Som Innovation Biotech S.L. Sustained release composition comprising micronized tolcapone
EP3765003A4 (en) * 2018-03-12 2022-01-26 Corino Therapeutics, Inc. COMBINATION THERAPY FOR TTR AMYLOIDOSIS
BR112021024151A2 (pt) * 2019-05-31 2022-02-08 Plex Pharmaceuticals Inc Agentes farmacológicos para tratamento de doenças de agregação de proteínas do olho
CN114324693B (zh) * 2022-01-14 2023-01-13 大连博源医学科技有限公司 一种血液中转甲状腺素蛋白(ttr)四聚体浓度测定的预处理方法和检测方法
WO2024081554A2 (en) * 2022-10-10 2024-04-18 Corino Therapeutics, Inc. Modified release tolcapone formulations

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5744368A (en) 1993-11-04 1998-04-28 Research Foundation Of State University Of New York Methods for the detection of soluble amyloid β-protein (βAP) or soluble transthyretin (TTR)
WO1998027972A2 (en) 1996-12-23 1998-07-02 Texas A & M University Anti-amyloidogenic agents
FI20002044A0 (fi) 2000-09-15 2000-09-15 Orion Yhtymae Oyj Comt-entsyymiä estäviä naftaleenijohdannaisia
DK1372682T3 (da) 2001-03-15 2012-08-20 Proteotech Inc Catechiner til behandling af fibrillogenese ved alzheimers sygdom, parkinsons sygdom, systemisk AA amyloidose og andre amyloide forstyrrelser
WO2003063880A1 (en) 2002-01-29 2003-08-07 Protemix Corporation Limited Disruption of islet amyloid by polycyclic compounds
US20040175382A1 (en) 2003-03-06 2004-09-09 Schafer Peter H. Methods of using and compositions comprising selective cytokine inhibitory drugs for the treatment and management of disorders of the central nervous system
CN1921856A (zh) * 2004-02-20 2007-02-28 诺瓦提斯公司 用于治疗神经变性疾病和认知障碍的dpp－iv抑制剂
AU2005215136A1 (en) 2004-02-20 2005-09-01 Novartis Ag DPP-IV inhibitors for treating neurodegeneration and cognitive disorders
CN101198598A (zh) * 2004-05-20 2008-06-11 弗尔德里克斯制药股份有限公司 2-((杂)芳基)-苯并噁唑化合物及其衍生物、组合物以及用于稳定和抑制甲状腺素转运蛋白错重叠的方法
CN101035541B (zh) 2004-08-30 2012-05-30 柳署弘 溶解的udca在局灶缺血模型中的神经保护作用
GB2429645A (en) 2006-03-10 2007-03-07 Sekhsaria Chemicals Ltd Solid pharmaceutical composition comprising a COMT inhibitor, a starch and a wetting agent
US20120016037A1 (en) 2006-07-24 2012-01-19 Frank Toppo Method for prevention and treatment of Alzheimers
GB0718718D0 (en) 2007-09-25 2007-11-07 Pentraxin Therapeutics Ltd Compound and use thereof
DE102010010572A1 (de) 2010-03-08 2011-09-08 Mahle International Gmbh Trockenseparator
PT2770988T (pt) * 2011-10-24 2016-09-05 Som Innovation Biotech S L Nova terapêutica para a amiloidose associada à transtirretina

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
KLABUNDE T. et al. Rational design of potent transthyretin amyloid disease inhibitors. Nat.Struct.Biol. 2000 Apr;7(4): 312-21 [он лайн] [найдено 29.08.2016] (Найдено из Интернет: www.ncbi.nlm.nih.gov/pubmed/10742177)WO03/013442 А2 20.02.2003US2010/0249233 A1 30.09.2010RU2394570 C2 20.07.2010GB2429645 A 07.03.2007GALES L. et al. Human transthyretin in complex with iododiflunisal: structural features associated with a potent amyloid inhibitor. Biochem.J. 2005 Jun 1;388(Pt 2); 615-21 Реферат [он лайн] [найдено 26.08.2016] (Найдено из Интернет: www.ncbi.nlm.nih.gov/pubmed/1569188)RU2428987 C2 20.09.2011GUPTA S. et al. Design of mechanism-based inhibitors of transthyretin amyloidosis: studies with biphenyl ethers and new structural templates. J.Med.Chem. 2007 Nov 15; 50(23): 5589-99 Реферат [он лайн] [найдено 29.08.2016] (Найдено из Интернет: www.ncbi.nlm.nih.gov/pubmed/17948976)Fx-1006A CID24970412 Реферат [он лайн] [найдено 29.08.2016] (Найдено из Интернет: pubchem.ncbi.nlm.nih.gov/substa *
WO2003/063880 A1 07.08.2003WO2011/100396 A2 18.08.2011US2005/0282780 A1 22.12.2005WO2008/013764 A2 31.01.2008KLABUNDE T. et al. Rational design of potent transthyretin amyloid disease inhibitors. Nat.Struct.Biol. 2000 Apr;7(4): 312-21 [он лайн] [найдено 29.08.2016] (Найдено из Интернет: www.ncbi.nlm.nih.gov/pubmed/10742177)WO03/013442 А2 20.02.2003US2010/0249233 A1 30.09.2010RU2394570 C2 20.07.2010GB2429645 A 07.03.2007GALES L. et al. Human transthyretin in complex with iododiflunisal: structural features associated with a potent amyloid inhibitor. Biochem.J. 2005 Jun 1;388(Pt 2); 615-21 Реферат [он лайн] [найдено 26.08.2016] (Найдено из Интернет: www.ncbi.nlm.nih.gov/pubmed/1569188)RU2428987 C2 20.09.2011GUPTA S. et al. Design of mechanism-based inhibitors of transthyretin amyloidosis: studies with biphenyl ethers and new structural templates. J.Med.Chem. 2007 Nov 15; 50(23): 5589-99 Реферат [он лайн] [найдено 29.08.2016] (Найдено из Интернет: www.ncbi.nlm.nih.gov/pubmed/17948976)Fx-1 *

Also Published As

Publication number Publication date
AU2012327275A1 (en) 2014-04-17
IL231907B (en) 2018-05-31
US20170304243A1 (en) 2017-10-26
BR112014009322A2 (pt) 2017-04-18
US20190091188A1 (en) 2019-03-28
SG11201401215VA (en) 2014-08-28
RU2747536C2 (ru) 2021-05-06
US20140296188A1 (en) 2014-10-02
CA2852808C (en) 2021-07-06
US9610270B2 (en) 2017-04-04
MX385516B (es) 2025-03-18
MX2014004863A (es) 2014-05-27
HK1198432A1 (en) 2015-04-24
MX347784B (es) 2017-05-12
CL2014000893A1 (es) 2014-09-05
AU2012327275A2 (en) 2014-04-17
PL2770988T3 (pl) 2017-01-31
BR112014009322A8 (pt) 2018-01-16
US10786473B2 (en) 2020-09-29
IL231907A0 (en) 2014-05-28
AU2017202670B2 (en) 2019-06-06
US20200138760A1 (en) 2020-05-07
KR102017354B1 (ko) 2019-09-02
NZ623267A (en) 2015-11-27
US10045956B2 (en) 2018-08-14
CN103889407A (zh) 2014-06-25
AU2017202670A1 (en) 2017-05-11
CY1118151T1 (el) 2017-06-28
US10449169B2 (en) 2019-10-22
RU2017119539A (ru) 2018-11-09
ZA201402546B (en) 2015-07-29
JP6068484B2 (ja) 2017-01-25
SG10201609933WA (en) 2017-02-27
BR112014009322B1 (pt) 2022-05-10
RU2017119539A3 (enExample) 2020-06-29
PT2770988T (pt) 2016-09-05
RU2014114930A (ru) 2015-12-10
WO2013060668A1 (en) 2013-05-02
CN103889407B (zh) 2017-03-15
US11564899B2 (en) 2023-01-31
EP2770988B1 (en) 2016-07-20
EP2770988A1 (en) 2014-09-03
US20200390733A1 (en) 2020-12-17
CA2852808A1 (en) 2013-05-02
JP2014530842A (ja) 2014-11-20
AU2012327275B2 (en) 2017-03-02
KR20140090161A (ko) 2014-07-16
ES2593038T3 (es) 2016-12-05

Similar Documents

Publication Publication Date Title
US11564899B2 (en) Therapy for transthyretin-associated amyloidosis
EP2397139B1 (en) Anti-neurodegenerative disease agent
JP2023085274A (ja) 細胞生存率を向上させるための組成物およびその使用方法
KR100676124B1 (ko) 엔-[2-히드록시-3-(1-피페리디닐)프로폭시]피리딘-1-옥사이드-3-카르복시미도일 클로라이드 및 인슐린 내성 치료에 있어서의 이의 용도
US9486430B2 (en) Treatment of neurodegenerative disease
DE69832695T2 (de) Verwendung von r-enantiomeren nichtsteroidaler entzündungshemmer zur vorbeugung der alzheimerschen krankheit
Yang et al. Perampanel, an AMPAR antagonist, alleviates experimental intracerebral hemorrhage‑induced brain injury via necroptosis and neuroinflammation
CN103169694B (zh) 正丁烯基苯酞在制造用于治疗肝损伤和改善肝功能的药物中的用途及药物组合物
JP2005500346A (ja) タウフィラメント形成重合を阻害するかまたは逆転させる方法
US20210069139A1 (en) Stabilization of transthyretin tetramers in biological fluids
NZ623267B2 (en) New therapy for transthyretin-associated amyloidosis
HK1198432B (en) Therapy for transthyretin-associated amyloidosis
Hamo MPTP model of Parkinson's disease: Mechanisms of neurodegeneration and potential neuroprotective compounds
HK40004918B (en) Compositions for improving cell viability and methods of use thereof